30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Michael McManus

Track

Insider profile

Currently holds a position at Eastern Co

Performance

Overall performance
4.0
Performance over holding periods
4.0
30 days 90 days 120 days
Average return 16% 8.2% 15.1%
Success rate 60% 68% 82%
Transactions
7 43% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Eastern Co Jan. 1, 2015 -
Michael McManus's trades of United States Antimony Corp's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-01 2025-10-01
PrS Proposed sale
49,428
297.67
US$612,664 		49,428 297.67 US$612,664
2024-12-11 2024-12-10
B Purchase
49,453 +46.2%
415.45
US$4,994,551 		49,453 +46.2% 415.45 US$4,994,551
2024-11-19 2024-11-18
B Purchase
53,276 -47.0%
219.71
US$4,223,414 		53,276 -47.0% 219.71 US$4,223,414
2024-08-15 2024-08-14
B Purchase
135,000 +162.0%
0.38
US$51,705 		135,000 +162.0% 0.38 US$51,705
2021-03-23 2021-03-19
US Novavax Inc (NVAX)
S Sale
3,000 -33.5%
220.57
US$661,710 		3,000 -33.5% 220.57 US$661,710
2021-03-23 2021-03-19
US Novavax Inc (NVAX)
S Sale
1,000 -10.0%
221.40
US$221,400 		1,000 -10.0% 221.40 US$221,400
2020-08-20 2020-08-18
US Novavax Inc (NVAX)
S Sale
8,000 -44.6%
146.00
US$1,168,000 		8,000 -44.6% 146.00 US$1,168,000
2019-11-20 2019-11-18
US Novavax Inc (NVAX)
S Sale
3,929 -28.3%
3.82
US$15,015 		3,929 -28.3% 3.82 US$15,015